IL325237A - תרכובות הטרואריל-אמין והשימוש בהן כמעכבי hdac6 - Google Patents

תרכובות הטרואריל-אמין והשימוש בהן כמעכבי hdac6

Info

Publication number
IL325237A
IL325237A IL325237A IL32523725A IL325237A IL 325237 A IL325237 A IL 325237A IL 325237 A IL325237 A IL 325237A IL 32523725 A IL32523725 A IL 32523725A IL 325237 A IL325237 A IL 325237A
Authority
IL
Israel
Prior art keywords
heteroaryl
amine compounds
hdac6 inhibitors
hdac6
inhibitors
Prior art date
Application number
IL325237A
Other languages
English (en)
Original Assignee
Augustine Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Augustine Therapeutics filed Critical Augustine Therapeutics
Publication of IL325237A publication Critical patent/IL325237A/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL325237A 2023-06-21 2025-12-09 תרכובות הטרואריל-אמין והשימוש בהן כמעכבי hdac6 IL325237A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23180701 2023-06-21
PCT/EP2024/067567 WO2024261329A1 (en) 2023-06-21 2024-06-21 Heteroaryl-amine compounds and use thereof as hdac6 inhibitors

Publications (1)

Publication Number Publication Date
IL325237A true IL325237A (he) 2026-02-01

Family

ID=86942713

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325237A IL325237A (he) 2023-06-21 2025-12-09 תרכובות הטרואריל-אמין והשימוש בהן כמעכבי hdac6

Country Status (4)

Country Link
CN (1) CN121532190A (he)
AU (1) AU2024314277A1 (he)
IL (1) IL325237A (he)
WO (1) WO2024261329A1 (he)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017053360A1 (en) * 2015-09-22 2017-03-30 The Board Of Trustees Of The University Of Illinois Bicyclic and tricyclic cap bearing mercaptoacetamide derivatives as histone deacetylase inhibitors
US11584733B2 (en) * 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
ES2749743B2 (es) * 2018-09-21 2020-12-14 Consejo Superior Investigacion Derivados de purina inhibidores de cdc7 y su uso para el tratamiento de patologias neurologicas
US11339150B2 (en) * 2019-12-27 2022-05-24 Onkure, Inc. Benzimidazole compounds as HDAC6 inhibitors
EP4111863A1 (en) * 2021-07-02 2023-01-04 EuroChem Antwerpen Phosphorus use efficiency enhancers as plant growth promotors
KR20240124952A (ko) * 2021-12-22 2024-08-19 어거스틴 테라퓨틱스 Hdac6 억제제로서의 화합물 및 이의 용도

Also Published As

Publication number Publication date
AU2024314277A1 (en) 2025-11-13
CN121532190A (zh) 2026-02-13
WO2024261329A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
IL313636A (he) תרכובות ושימוש בהן כמעכבי hdac6
IL325094A (he) מעכבי pi3k-אלפא ושיטות לשימוש בהם
SG11202107615TA (en) Pcsk9 inhibitors and methods of use thereof
IL287751A (he) מעכבי kcnt1 ושיטות לשימוש
EP4071155A4 (en) THIAZOLOLACTAM COMPOUND USED AS ERK INHIBITOR AND USE THEREOF
PL4084778T3 (pl) Formulacje amorficznych inhibitorów kinazy i sposoby ich zastosowania
SG11202112158YA (en) Kcnt1 inhibitors and methods of use
SG11202112277PA (en) Acss2 inhibitors and methods of use thereof
IL312348A (he) מעכבי hif-2alpha ושיטות השימוש בו
IL289649A (he) פורמולציות של מעכבי rbp4 ושיטות לשימוש
IL325232A (he) מעכבי pi3k ושימוש בהם
ZA202109737B (en) Compound used as kinase inhibitor and application thereof
IL287293A (he) מעכבים לעריכת רנא ושיטות לשימוש
IL285595A (he) מעכבים של spt5 ושימוש בהם
EP3959197A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
IL312466A (he) מעכבי pi3k-אלפא ושיטות להכנה ולשימוש בהם
GB202214644D0 (en) Sars-cov-2 mpro inhibitors and uses thereof
PT4084778T (pt) Formulações de inibidores de quinase amorfas e métodos de utilização das mesmas
IL311588A (he) מעכבי lpxc ושימושים בהם
ZA202105833B (en) Arginase inhibitors and methods of use thereof
IL325237A (he) תרכובות הטרואריל-אמין והשימוש בהן כמעכבי hdac6
HK40117385A (en) Compounds and use thereof as hdac6 inhibitors
CA3291049A1 (en) Heteroaryl-amine compounds and use thereof as hdac6 inhibitors
IL319927A (he) תרכובות והשימוש בהן
GB202303237D0 (en) Compounds and their use